ENTA: Enanta Price to Sales

Corporate company logo of Enanta Pharmaceuticals, Inc (ENTA)

Enanta Pharmaceuticals (ENTA) generates revenue through royalties from hepatitis treatments and government healthcare support. The price-to-sales valuation reflects volatility driven by sanctions pressure on raw materials and testing barriers. Meanwhile, a robust R&D pipeline and partnerships with industry behemoths provide stability. The current level of 4.90 indicates the asset's real-time market value relative to its actual earnings.

ENTA (Enanta Pharmaceuticals) P/S Multiple history from 07/04/2022 to 11/14/2026

Enanta (ENTA) - metric breakdowns and financial figures

- price and consensus price forecast:
Market Chart Enanta Pharmaceuticals, Inc.|ENTA - Analyst Consensus Forecast
- market capitalization information:
Market Value Enanta Pharmaceuticals|ENTA - Total Company Value
- shareholders' equity book value data:
Equity per Share Enanta Pharmaceuticals|ENTA - Book Capitalization|Market Capitalization to Book Value Ratio enanta.com|ENTA - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio Enanta Pharmaceuticals|ENTA - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Enanta Pharmaceuticals|ENTA - Company Aggregate Debts|Debts to Book Capitalization Enanta Pharmaceuticals, Inc.|ENTA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Enanta Pharmaceuticals|Critical Liquidity Ratio enanta.com
- net income and valuation multiples indicators:
ENTA - Net Profit|Expected Net Income Enanta Pharmaceuticals|ENTA - P/E Multiple|Forward P/E Multiple Enanta Pharmaceuticals, Inc|ENTA - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Enanta Pharmaceuticals|ENTA - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Enanta Pharmaceuticals|ENTA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth enanta.com|ENTA - Earnings growth in current year|Expected earnings per share growth for next year Enanta Pharmaceuticals
- issuer revenue and sales details:
ENTA - Revenue and Sales Volume|Company Expected Sales Volume Enanta|ENTA - Market Cap to Revenue|Forward P/S Multiple Enanta Pharmaceuticals, Inc.
General company analysis:ENTA Enanta
Manufactured products of Enanta Pharmaceuticals Inc.

The P/S ratio measures the market value of a business relative to its sales volume, allowing for the determination of an asset's overvaluation depending on the phase of the economic cycle. By analyzing the price-to-sales ratio on the GURU.Markets platform, an investor assesses the monetization efficiency of Enanta Pharmaceuticals (ENTA) antiviral therapies, including royalties from hepatitis C drugs and the potential of new developments to combat RSV and COVID-19.

Who Enanta Pharmaceuticals competes with

Price-to-Revenue Coefficient Gilead Sciences|P/S Multiple CDTX (Cidara Therapeutics)|NVAX: Market Cap to Revenue Ratio|CVAC: Market Cap to Revenue|VALN - P/S Multiple|VIR (Vir Biotechnology) - Market Cap to Revenue|Price-to-Revenue Multiple SIGA Technologies SIGA|EBS (Emergent BioSolutions Inc) - P/S Multiple|P/S Multiple Atea Pharmaceuticals|Market Cap to Revenue IVVD (Invivyd)|INO - Price to Sales|HilleVax - Market Cap to Revenue|Price-to-Revenue Coefficient Kalaris Therapeutics Inc. (KLRS)|DYAI: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio NNVC (nanoviricides.com)|TLPH: P/S Multiple|cocrystalpharma.com (COCP) - P/S Multiple|TRAW (Traws Therapeutics) - P/S Multiple|DWTX (Dogwood Therapeutics, Inc.) - Market Cap to Sales Volume|Market Cap to Revenue QLGN (Qualigen Therapeutics, Inc.)|AlloVir - Market Cap to Revenue Ratio|P/S Multiple VBIV (VBI Vaccines)|Market Capitalization-to-Revenue Ratio VIRI|VXRT: Market Cap to Revenue